Therapeutic Approaches for Inhibition of Protein Aggregation in Huntington's Disease

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Huntington's disease (HD) is a progressive neurodegenerative disorder.
• It is caused by the aggregation of mutant huntingtin protein with expanded polyglutamine.
• Molecular chaperones play a crucial role in preventing protein aggregation and neurodegeneration.

Purpose of the Study:

• To review the function of molecular chaperones in animal models of Huntington's disease.
• To discuss therapeutic approaches targeting molecular chaperones.
• To explore the development of anti-aggregation drugs for HD.

Main Methods:

• Review of existing literature on molecular chaperones and Huntington's disease.
• Analysis of studies using animal models of HD.
• Examination of therapeutic strategies involving chaperone modulation and anti-aggregation drugs.

Main Results:

• Molecular chaperones mitigate neurodegeneration in HD animal models by inhibiting mutant huntingtin aggregation.
• Chaperone-inducible drugs and anti-aggregation drugs demonstrate beneficial effects on HD symptoms.
• Modulating chaperone expression and turnover are viable therapeutic avenues.

Conclusions:

• Molecular chaperones are key protective factors in Huntington's disease.
• Targeting molecular chaperones and protein aggregation offers promising therapeutic strategies for HD.
• Further research into chaperone-modulating and anti-aggregation drugs is warranted for HD treatment.